Weight Watchers is making a bold move by acquiring Sequence, a telehealth service specializing in weight loss drugs, including the highly effective Ozempic. With research showing significant weight loss results, this acquisition has already led to a remarkable 70% surge in Weight Watchers' stock. The deal, valued at $106 million, signals a strategic shift towards integrating medical solutions in the weight loss industry.
